The purpose of this study is to evaluate the safety and tolerability of one-time subcutaneous
(SC) administration of monoclonal antibody (MAb) L9LS in healthy Kenyan children aged 5
months to 10 years, as well as the protective efficacy of one or two doses of L9LS against
naturally occurring Plasmodium falciparum (Pf) infection among Kenyan children aged 5 to 59
months at enrollment, in a setting of perennial high transmission.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators:
Centers for Disease Control and Prevention Kenya Medical Research Institute Liverpool School of Tropical Medicine (LSTM) National Institutes of Health (NIH) Vaccine Research Center (VRC)